Compare Alcon AG (ALC) vs Intel Corp (INTC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Intel Corp — how do they compare? Alcon AG trades at $66.95 (market cap $32.69B), while Intel Corp trades at $106.78 (market cap $554.82B). The key difference: Intel Corp is far larger — about 17× Alcon AG's market cap, and Intel Corp pays the higher dividend (2.24%). Which is the better fit depends on your goals.
| ALC | INTC | |
|---|---|---|
Market Cap | $32.69B | $554.82B |
Sector | Health | Technology |
52-Week High | $92.22 | $140.94 |
52-Week Low | $62.02 | $19.31 |
Enterprise Value | $36.28B | $567.06B |
Dividend Yield | 0.54% | 2.24% |
Volume | — | 43,552,012 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Intel (INTC) trades at $110.39, down 8.28% amid a sector-wide chip selloff triggered by Samsung's earnings reaction. Despite beating EPS estimates for three consecutive quarters, the stock shows weak profitability with a negative net income margin and ROE. Technical indicators are neutral, with support at $114 and resistance at $124. Cash flow improved in 2025, but revenue remains flat year-over-year, highlighting growth challenges.
The outlook is mixed: analyst consensus is a 'Hold' with a $97.74 price target below current levels, reflecting skepticism about near-term execution. Risks include intense competition and cyclical semiconductor demand, but potential upside exists if foundry partnerships and AI-driven CPU demand materialize as projected by bullish analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →
